Physician profile
John S Perry
NPI 1942220223
$5,711.70
in general payments reported to CMS, 2019-2025
34 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $477 · 2021: $647 · 2022: $622 · 2023: $1,059 · 2024: $1,026 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,237.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,268.95 | 2021-2025 | |
| Novo Nordisk INC | $819.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $424.63 | 2019-2020 | |
| Glaxosmithkline, LLC. | $407.21 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $380.54 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $295.69 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $287.79 | 2019-2025 | |
| Axsome Therapeutics, INC. | $195.05 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $188.56 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $159.96 | 2019-2023 | Trintellix |
| Abbott Laboratories | $159.19 | 2019-2023 | Freestyle Libre 3 |
| Stryker Corporation | $138.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $136.91 | 2020 | |
| Phathom Pharmaceuticals, INC. | $121.87 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.86 | 2021-2023 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $88.39 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $58.04 | 2019-2023 | |
| Edwards Lifesciences Corporation | $46.21 | 2025 | |
| Corcept Therapeutics | $45.82 | 2023 | Korlym |
| Verona Pharma, INC. | $44.45 | 2025 | Ohtuvayre |
| Irhythm Technologies, INC. | $37.62 | 2023 | Zio Xt Patch |
| Corium, LLC | $35.34 | 2023-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $31.00 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.48 | 2022 | |
| Exact Sciences Corporation | $28.84 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $25.51 | 2019 | |
| Astellas Pharma US INC | $24.77 | 2023 | Veozah |
| Nevro Corp. | $23.66 | 2019 | |
| Si-Bone, INC. | $22.19 | 2019 | |
| Dexcom, INC. | $17.45 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $16.89 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.78 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $12.84 | 2021 | |
| Neuronetics, INC. | $10.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.